DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for molluscum contagiosum — screening already-approved drugs against its 3-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleMolluscum contagiosum maps to a 3-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for molluscum contagiosum is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
retinoic acid receptor gamma (RARG) — RARG is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 1-adamantyldrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6FX0 · 1.9 Å · ligand 6-[3-(1-adamantyl)-4-oxidanyl-phenyl]naphthalene-2-carboxylic acid (E9T). Experimental structure, not a prediction.
What the evidence adds up to
Molluscum contagiosum is a skin condition caused by a large virus and may spread through public swimming baths, infected garments, and contaminated cosmetics and fingers, involving the face, hands, and genitalia. When the lid margin is involved, particularly the upper lid, it induces conjunctivitis which is follicular in nature, and is sometimes accompanied by keratitis that may simulate trachoma. Molluscum nodules in the bulbar conjunctiva and on the cornea have been reported.
Lesions show a tendency towards spontaneous regression, which might be caused by antiviral proteins such as defensins. A study reported a marked increase in human beta-defensin 3 immunoreactivity in molluscum contagiosum lesions, in contrast to human beta-defensin 2, which was only marginally increased. The authors suggested a role for the hBD-3 peptide in the pathogenesis of the disease.
In a case report, a 24-year-old man receiving methotrexate and adalimumab for Crohn disease developed several small papules on his eyelid. The lesions were removed by shave biopsy, and microscopic examination revealed epidermal hyperplasia composed of keratinocytes filled with large eosinophilic intracytoplasmic inclusions. The patient applied mupirocin 2% ointment to the biopsy sites, which healed without complication or recurrence. Molluscum contagiosum generally resolves spontaneously within 18 months. Topical cantharidin or locally destructive therapy (curettage, cryotherapy, laser) may be indicated for patients concerned about persistent lesions and for children susceptible to autoinoculation.
What is still missing is any controlled trial data for treatments in molluscum contagiosum, particularly in immunocompromised populations where lesions may be more persistent. The role of defensins as a therapeutic target remains speculative without functional studies or clinical intervention. No randomised comparisons of destructive therapies versus observation have been published, and patient stratification by immune status or lesion burden has not been systematically addressed.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
British Journal of Ophthalmology · 1960 · 21 citations · open access
OCULAR COMPLICATIONS IN MOLLUSCUM CONTAGIOSUM
AbstractMOLLUSCUM contagiosum is a skin condition caused by a large virus. It may spread through public swimmling baths, infected garments, and contaminated cosmetics and fingers, and may involve the face, hands, and genitalia. When the lid margin is involved, particularly the upper lid, it induces conjunctivitis which is follicular in nature, and is sometimes accompanied by keratitis which may simulate trachoma (Sorsby, 1951). Molluscum nodules in the bulbar conjunctiva were reported by Ballaban (1903) and Redslob (1927), and on the cornea by Quill (1940).
Clinical and Experimental Dermatology · 2009 · 14 citations
Increased expression of human beta-defensin 3 in mollusca contagiosum
AbstractThe human beta defensins (hBDs)-2 and -3 are inducible antimicrobial peptides present in human skin. Besides an important role in fighting bacteria, they also have an antiviral function. Molluscum contagiosum (MC) is a cutaneous viral disease caused by the MC virus. Lesions show a tendency towards spontaneous regression, which might be caused by antiviral proteins such as defensins. We report a marked increase in hBD-3 immunoreactivity in MC lesions in contrast to hBD-2, which was only marginally increased. We suggest a role for the hBD-3 peptide in MC pathogenesis.
Molluscum contagiosum of the eyelid: case report in a man receiving methotrexate and literature review of molluscum contagiosum in patients who are immunosuppressed secondary to methotrexate or HIV infection
AbstractBACKGROUND: Molluscum contagiosum is a benign viral infection of the skin. Lesions typically present as dome-shaped, flesh-colored, umbilicated papules that range in size from 1 to 5 millimeters in diameter. They are usually asymptomatic, but can become tender or pruritic. Children and immunocompromised adults, including individuals being treated with immunosuppressive drugs, are most susceptible to infection. Single or multiple lesions most commonly appear on the extremities, face, genitals, and trunk. However, albeit rarely, molluscum contagiosum may also develop at other sites, including the eyelids. PURPOSE: We describe the clinical and pathologic findings of a man who developed molluscum contagiosum of the eyelid while receiving methotrexate. We also review the characteristics of other patients with molluscum contagiosum acquired either during treatment with methotrexate or associated with human immunodeficiency virus (HIV) infection and summarize the unusual sites of presentation for the viral lesions in these individuals. MATERIALS AND METHODS: The features of a man receiving methotrexate who developed molluscum contagiosum of the eyelid are presented. Using PubMed, the following terms were searched and relevant citations assessed: adalimumab, contagiosum, Enbrel, etanercept, Humira, infliximab, methotrexate, molluscum, Remicade, TNF alpha, and tumor necrosis factor alpha. In addition, the literature on methotrexate treatment and molluscum contagiosum is reviewed. RESULTS: Several small papules were observed on the eyelid of a 24-year-old man who had been receiving methotrexate and adalimumab (Humira) for the treatment of Crohn disease. The lesions were removed by shave biopsy. Microscopic examination revealed epidermal hyperplasia composed of keratinocytes filled with large eosinophilic intracytoplasmic inclusions. Based on correlation of the clinical presentation and histopathologic findings, a diagnosis of molluscum contagiosum was established. The patient applied mupirocin 2% ointment to the biopsy sites, which subsequently healed without complication or recurrence. CONCLUSION: Molluscum contagiosum is a benign viral papular eruption that frequently affects children and immunocompromised adults. Patients treated with immunosuppressive agents, such as methotrexate, have a heightened risk of developing molluscum contagiosum lesions. It remains to be determined whether adjunct therapy with a tumor necrosis factor alpha inhibitor increasesthe risk of this viral infection. Diagnosis can usually be established by clinical presentation, although a biopsy is sometimesrequired to exclude other conditions. Molluscum contagiosum is generally self-limiting and often resolves spontaneously within18 months. However, topical (cantharidin) or locally destructive (curettage, cryotherapy, and/or laser) therapy may be indic tedfor patients who are concerned about persistent lesions and for children who are particularly susceptible to autoinoculation.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
